Oxygenta Pharmaceutical share price
BSE: 524636Pharmaceuticals & BiotechnologySmall Cap
Last close ₹46.07down ₹0.93 (1.98%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹47.00.
52-week range of traded prices to 23 Oct 2026
₹43.00Low, 11 Jun 2026₹71.59High, 12 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 27 Jul 2026
- −15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,726
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 27 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹37 Crdown 25.43%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹2.10 CrQuarter to Mar 2026: −₹1.70 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −5.7%
Revenue by year
Peak revenue ₹113 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 9 of the 10 years shown
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 17 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 7 Nov | Dec 2025Filed 4 Feb | Mar 2026Filed 23 May | Jun 2026Filed 27 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.0 | 33.2 | 49.5 | 15.1 | 14.3 | 33.9 | 49.6 | 37.0 |
| Net profit | −2.9 | −3.9 | −2.2 | −6.1 | −4.9 | −4.8 | −1.7 | −2.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −20.4% | −11.8% | −4.4% | −40.3% | −34.5% | −14.3% | −3.4% | −5.7% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of Pharmaceutical Products, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −39.2% | – | – | 0.0% |
| 3 years | +9.7% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Oxygenta Pharmaceutical in market cap.
Oxygenta Pharmaceutical is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sanjivani ParanteralSANJIVIN | 188 | – | 3.9 | 13.5 | +13.2% | – | – | 20.2% | 0.00% |
 Coral LaboratoriesCORALAB | 177 | 9.2 | 0.8 | 5.8 | −5.4% | +7.2% | 9.4% | 7.6% | 0.40% |
 Kerala AyurvedaKERALAYUR | 171 | – | 15.3 | – | +10.4% | – | −257.3% | −24.1% | 0.00% |
 Brooks LaboratoriesBROOKS | 170 | 12.9 | 1.4 | 29.4 | −7.7% | +550.4% | 12.0% | 3.2% | 0.00% |
 Achyut HealthcareACHYUT | 168 | – | – | – | – | – | – | – | 0.00% |
 Syschem (India)SYSCHEM | 166 | – | – | – | +59.1% | – | – | 11.7% | 0.00% |
 Medico RemediesMEDICO | 165 | 12.0 | 2.2 | 10.4 | +50.0% | +33.7% | 20.1% | 15.3% | 0.00% |
 Smruthi OrganicsSMRUTHIORG | 153 | 20.7 | 2.1 | 8.5 | −4.6% | +118.2% | 10.2% | 14.8% | 1.12% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
1 Oct · Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Purchase Of Land
Aug 2026
Jul 2026
Oxygenta Pharmaceutical share price by year
Each calendar year to 2025.Oxygenta Pharmaceutical share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 55.79 | −36.2% | 124.58 | 54.00 |
| 2024 | 87.47 | +180.7% | 106.51 | 28.21 |
| 2023 | 31.16 | +9.9% | 48.76 | 22.00 |
| 2022 | 28.35 | +2.5% | 31.05 | 21.00 |
| 2021 | 27.65 | +278.8% | 36.55 | 9.57 |
| 2019 | 7.30 | −22.8% | 10.40 | 7.04 |
| 2018 | 9.45 | +32.5% | 9.79 | 5.24 |
| 2017 | 7.13 | −34.8% | 13.15 | 7.13 |
| 2016 | 10.93 | +27.4% | 11.50 | 9.00 |
| 2015 | 8.58 | +0.9% | 8.58 | 6.30 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 19 Jul 2021. The change in 2021 is on the close at the end of 2019, the last year before it with a trade. The close is the year's last trade for 2019 (25 Jul 2019) and 2016 (8 Nov 2016).
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 47.99 | 48.98 | 46.00 | 46.07 | 47.34 | 6,726 |
| 22 Oct 2026 | 46.60 | 48.89 | 46.60 | 47.00 | 47.25 | 8,682 |
| 21 Oct 2026 | 46.70 | 47.80 | 46.60 | 47.19 | 46.67 | 6,375 |
| 19 Oct 2026 | 48.49 | 48.49 | 46.60 | 46.60 | 47.51 | 2,849 |
| 16 Oct 2026 | 46.26 | 47.95 | 46.26 | 47.00 | 47.11 | 4,899 |
| 15 Oct 2026 | 47.00 | 47.00 | 46.10 | 46.26 | 46.35 | 2,558 |
| 14 Oct 2026 | 47.08 | 47.09 | 46.61 | 47.08 | 47.05 | 4,543 |
| 13 Oct 2026 | 47.53 | 49.18 | 46.50 | 47.09 | 47.74 | 11,335 |
| 12 Oct 2026 | 47.55 | 49.20 | 47.55 | 48.50 | 48.22 | 7,267 |
| 9 Oct 2026 | 48.74 | 48.74 | 47.30 | 48.60 | 48.41 | 3,568 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Open offer history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Jul 2021 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
| 12 Sep 2014 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- OXYGENTA PHARMACEUTICAL LIMITED
- BSE code
- 524636
- ISIN
- INE102E01018
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1994
- Face value
- ₹10
- CIN
- L24110TG1990PLC012038
- Corporate identity number, the registrar of companies' code for it